Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Bio-Rad Laboratories (BIO)

Bio-Rad swings to $341.9 million Q3 net loss on Sartorius stake; sales up 0.5%

Mixed Impact 3 of 5 earnings Written later

Bio-Rad reported third-quarter 2025 revenue of $653.0 million, up 0.5% from a year earlier but down 1.7% on a currency-neutral basis. A $495.3 million loss from the change in fair market value of its Sartorius AG investment drove a GAAP net loss of $341.9 million, or $12.70 per diluted share, compared with net income of $653.2 million a year earlier. The company kept its full-year 2025 non-GAAP outlook unchanged.

Key points

  • GAAP net loss of $341.9 million, or $12.70 per diluted share, versus net income of $653.2 million, or $23.34 per share, in Q3 2024
  • Non-GAAP net income of $60.8 million, or $2.26 per diluted share, versus $56.3 million, or $2.02 per share, a year earlier
  • Non-GAAP operating margin of 11.8% versus 11.3%; currency-neutral sales decreased 1.7%, with lower sales in both Life Science and Clinical Diagnostics
  • Full-year 2025 outlook maintained: non-GAAP currency-neutral revenue growth of approximately 0 to 1.0% and non-GAAP operating margin of approximately 12.0 to 13.0%

The filing

CompanyBio-Rad Laboratories (BIO)
Form8-K, current report
Filed with the SECOct 29, 2025, 4:16 PM ET
Accession number0000012208-25-000076

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.